Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
Source: [CNBC](https://www.cnbc.com/2026/07/11/glp-1-implant-from-vivani-medical-aims-to-help-patients-stay-on-treatment.html)